Access to Medicines: Case Studies from Russia and Kyrgyzstan

Liliya Eugenevna Ziganshina; Chinara M. Razzakova; Syed Shahzad Hasan; Zaheer-ud-din Babar

doi:10.1007/978-981-15-2724-1_8

Access to Medicines: Case Studies from Russia and Kyrgyzstan

Liliya Eugenevna Ziganshina, Chinara M. Razzakova, Syed Shahzad Hasan, Zaheer-ud-din Babar

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

We report medicine prices, availability and affordability in Russia and Kyrgyzstan using the WHO/HAI methodology. In Kyrgyzstan, median prices of cardiovascular medicines were 6 times higher than in Russia, whilst their affordability was 9 times lower than in Russia for lowest-priced generics and 11 times lower for originator brands. Antihypertensive pharmacotherapy was affordable in Russia, but not in Kyrgyzstan (2015). We monitored patient and procurement prices in Russia (2010–2017) and documented success of government interventions in reduction of essential and cardiovascular patient prices from 2010 onwards to recommended values for generics in public sector and the need for continued price monitoring.

Original language	English
Title of host publication	Global Pharmaceutical Policy
Editors	Zaheer-Ud-Din Babar
Publisher	Springer Singapore
Chapter	8
Pages	223-246
Number of pages	24
ISBN (Electronic)	9789811527241
ISBN (Print)	9789811527234
DOIs	https://doi.org/10.1007/978-981-15-2724-1_8
Publication status	Published - 16 Jun 2020

Access to Document

10.1007/978-981-15-2724-1_8Licence: Unspecified

Cite this

@inbook{84d7d988ea144151be2605e0da8b488c,

title = "Access to Medicines: Case Studies from Russia and Kyrgyzstan",

abstract = "We report medicine prices, availability and affordability in Russia and Kyrgyzstan using the WHO/HAI methodology. In Kyrgyzstan, median prices of cardiovascular medicines were 6 times higher than in Russia, whilst their affordability was 9 times lower than in Russia for lowest-priced generics and 11 times lower for originator brands. Antihypertensive pharmacotherapy was affordable in Russia, but not in Kyrgyzstan (2015). We monitored patient and procurement prices in Russia (2010–2017) and documented success of government interventions in reduction of essential and cardiovascular patient prices from 2010 onwards to recommended values for generics in public sector and the need for continued price monitoring.",

keywords = "Medicine prices, WHO/HAI pricing methodology, Lowest-price generic, Originator brand, Availability, Affordability, Access to medicines, Lowest-priced generic",

author = "Ziganshina, {Liliya Eugenevna} and Razzakova, {Chinara M.} and Hasan, {Syed Shahzad} and Zaheer-ud-din Babar",

year = "2020",

month = jun,

day = "16",

doi = "10.1007/978-981-15-2724-1_8",

language = "English",

isbn = "9789811527234",

pages = "223--246",

editor = "Zaheer-Ud-Din Babar",

booktitle = "Global Pharmaceutical Policy",

publisher = "Springer Singapore",

address = "Singapore",

}

TY - CHAP

T1 - Access to Medicines

T2 - Case Studies from Russia and Kyrgyzstan

AU - Ziganshina, Liliya Eugenevna

AU - Razzakova, Chinara M.

AU - Hasan, Syed Shahzad

AU - Babar, Zaheer-ud-din

PY - 2020/6/16

Y1 - 2020/6/16

N2 - We report medicine prices, availability and affordability in Russia and Kyrgyzstan using the WHO/HAI methodology. In Kyrgyzstan, median prices of cardiovascular medicines were 6 times higher than in Russia, whilst their affordability was 9 times lower than in Russia for lowest-priced generics and 11 times lower for originator brands. Antihypertensive pharmacotherapy was affordable in Russia, but not in Kyrgyzstan (2015). We monitored patient and procurement prices in Russia (2010–2017) and documented success of government interventions in reduction of essential and cardiovascular patient prices from 2010 onwards to recommended values for generics in public sector and the need for continued price monitoring.

AB - We report medicine prices, availability and affordability in Russia and Kyrgyzstan using the WHO/HAI methodology. In Kyrgyzstan, median prices of cardiovascular medicines were 6 times higher than in Russia, whilst their affordability was 9 times lower than in Russia for lowest-priced generics and 11 times lower for originator brands. Antihypertensive pharmacotherapy was affordable in Russia, but not in Kyrgyzstan (2015). We monitored patient and procurement prices in Russia (2010–2017) and documented success of government interventions in reduction of essential and cardiovascular patient prices from 2010 onwards to recommended values for generics in public sector and the need for continued price monitoring.

KW - Medicine prices

KW - WHO/HAI pricing methodology

KW - Lowest-price generic

KW - Originator brand

KW - Availability

KW - Affordability

KW - Access to medicines

KW - Lowest-priced generic

UR - https://www.springer.com/gp/book/9789811527234?utm_campaign=bookpage_about_buyonpublisherssite&utm_medium=referral&utm_source=springerlink

UR - http://www.scopus.com/inward/record.url?scp=85089645081&partnerID=8YFLogxK

U2 - 10.1007/978-981-15-2724-1_8

DO - 10.1007/978-981-15-2724-1_8

M3 - Chapter

SN - 9789811527234

SP - 223

EP - 246

BT - Global Pharmaceutical Policy

A2 - Babar, Zaheer-Ud-Din

PB - Springer Singapore

ER -

Access to Medicines: Case Studies from Russia and Kyrgyzstan

Abstract

Access to Document

Other files and links

Fingerprint

Cite this